Pipettes take small molecule inhibitors from discovery to clinical trials

INTEGRA'S liquid handling solutions have helped RAPT Therapeutics' R&D team to efficiently analyze its lead drug candidates at every stage of the process – from discovery to clinical trials – driving its innovative therapies towards commercialization.

RAPT Therapeutics is a clinical stage, immunology-based biopharmaceutical company focused on small molecule therapies for various cancers and inflammatory diseases. It currently has two promising candidates in clinical trials. The company’s immunology laboratory uses INTEGRA pipettes to help develop and perform assays to characterize immune cell subsets after disease onset and drug administration, answering important questions that may arise before or after clinical trials.

Steven Lomeli Gonzalez, research associate in RAPT Therapeutics' Immunology Department, explains, “I work with EVOLVE manual pipettes and VIAFLO 96 electronic pipettes on a day-to-day basis, and find their performance outstanding. The VIAFLO 96 pipettes have been particularly useful for improving our productivity – which is critical for moving onto the next stage of a project – as we can dispense entire 96 well plates in one go.”

He continues, “With our efficient, ergonomic and accurate pipettes, we can continue to progress our small molecule inhibitors through clinical trials to improve cancer and autoimmune disease treatment. We all know someone that has been impacted by these disease areas, and we hope that getting our candidates to market quicker can help to improve the prognosis for patients in the future.”

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>